Axa bought a new position in shares of XOMA Co. (NASDAQ:XOMA) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 34,006 shares of the biotechnology company’s stock, valued at approximately $1,211,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of XOMA. Bogle Investment Management L P DE purchased a new stake in XOMA during the 4th quarter worth about $3,657,000. Geode Capital Management LLC increased its holdings in XOMA by 40.9% during the 4th quarter. Geode Capital Management LLC now owns 61,281 shares of the biotechnology company’s stock worth $2,180,000 after purchasing an additional 17,790 shares during the period. Allianz Asset Management GmbH purchased a new stake in XOMA during the 4th quarter worth about $328,000. Citadel Advisors LLC purchased a new stake in XOMA during the 4th quarter worth about $479,000. Finally, Wells Fargo & Company MN increased its holdings in XOMA by 4,288.9% during the 4th quarter. Wells Fargo & Company MN now owns 8,295 shares of the biotechnology company’s stock worth $295,000 after purchasing an additional 8,106 shares during the period. 38.90% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Several equities research analysts have weighed in on XOMA shares. TheStreet upgraded XOMA from an “e+” rating to a “c-” rating in a report on Wednesday, November 29th. HC Wainwright set a $38.00 price target on XOMA and gave the stock a “buy” rating in a report on Thursday, December 7th. Wedbush restated a “buy” rating and set a $33.00 price target on shares of XOMA in a report on Tuesday, December 19th. Zacks Investment Research downgraded XOMA from a “buy” rating to a “hold” rating in a report on Wednesday, February 21st. Finally, ValuEngine upgraded XOMA from a “sell” rating to a “hold” rating in a report on Friday, March 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $38.33.

XOMA stock opened at $21.82 on Thursday. XOMA Co. has a 1-year low of $5.36 and a 1-year high of $37.25. The company has a market capitalization of $186.15, a PE ratio of -41.17 and a beta of 3.03. The company has a debt-to-equity ratio of 2.52, a current ratio of 5.96 and a quick ratio of 5.96.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.19. XOMA had a negative return on equity of 130.44% and a net margin of 27.49%. The business had revenue of $5.36 million for the quarter, compared to the consensus estimate of $4.12 million. sell-side analysts forecast that XOMA Co. will post -1.24 earnings per share for the current year.

WARNING: “Axa Invests $1.21 Million in XOMA Co. (XOMA) Stock” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/axa-invests-1-21-million-in-xoma-co-xoma-stock/1955180.html.

XOMA Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Want to see what other hedge funds are holding XOMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for XOMA Co. (NASDAQ:XOMA).

Institutional Ownership by Quarter for XOMA (NASDAQ:XOMA)

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.